Core Insights - Global sleep health awareness is increasing, but there is a significant action gap where individuals recognize the importance of sleep yet fail to take steps to improve their sleep quality [2][3][10] Awareness and Action Gap - 53% of respondents consider sleep the most important factor for long-term health, surpassing diet and exercise, yet many do not take meaningful actions to enhance their sleep [2][7] - 84% of respondents acknowledge that consistent, quality sleep can extend a healthy lifespan, but 53% report getting quality sleep only four nights a week or less [3][7] Opportunities for Improvement - There is a clear opportunity to enhance education, screening, and diagnosis to help individuals identify sleep issues earlier and access care pathways [5] - The rise in wearable technology for sleep tracking has increased awareness, with usage among respondents growing from 16% in 2025 to 53% in 2026 [8] Gender Disparities - Nearly half of women surveyed (48%) struggle to fall asleep, an increase from 38% in 2025, with stress and anxiety being significant barriers [9] - Family responsibilities negatively impact sleep for 39% of women compared to 33% of men, highlighting a gender gap in sleep quality [9] Mental Health Connection - Insufficient sleep is linked to higher risks of anxiety and depression, with over a third of respondents reporting increased irritability (36%) and stress (33%) after poor sleep [9] Workplace Impact - More than half of respondents (58%) believe heavy workloads negatively affect their sleep, and 70% report taking a "snooze day" after a poor night's sleep [9] Relationship Dynamics - Sleeping together is associated with stronger intimacy, with 53% of respondents noting a positive impact on their sex life, although 80% experience some level of partner-related sleep disruption [9]

Core Insights - The 2026 Resmed Global Sleep Survey indicates a growing awareness of sleep health globally, yet a significant action gap persists between recognizing the importance of sleep and taking steps to improve sleep quality [2][3][4]. Awareness and Action Gap - Over half (53%) of respondents consider sleep the most important factor for long-term health, surpassing diet and exercise, but many do not take meaningful actions to enhance their sleep [2][7]. - Despite 84% of respondents acknowledging that quality sleep can extend a healthy lifespan, 53% report achieving a good night's sleep only four nights a week or less, illustrating the disconnect between awareness and action [3][4]. Opportunities for Improvement - The findings highlight a clear opportunity for enhanced education, screening, and diagnosis to help individuals identify sleep issues earlier and access appropriate care pathways [5]. - Increased use of wearable technology for sleep tracking has surged from 16% in 2025 to 53% in 2026, with 62% of wearable users indicating they would seek medical advice if their device flagged a potential risk [8]. Gender Disparities - Nearly half (48%) of women surveyed struggle to fall asleep, an increase from 38% in 2025, with stress and anxiety cited as significant barriers [9]. - Family responsibilities negatively impact sleep for 39% of women compared to 33% of men, further widening the gender gap in sleep quality [9]. Mental Health and Sleep - Insufficient sleep is linked to higher risks of anxiety and depression, with over a third of respondents reporting increased irritability (36%) and stress (33%) after poor sleep [9]. - A quarter (25%) of respondents globally reported feelings of depression following inadequate sleep [9]. Workplace Impact - More than half (58%) of respondents believe heavy workloads adversely affect their sleep, and 70% have taken a "snooze day" due to poor sleep [9]. - Flexible working arrangements are seen as beneficial by 59% of respondents in managing their sleep [9]. Relationship Dynamics - Sleeping together is associated with improved intimacy, with 53% of respondents noting a positive impact on their sex life, while 39% report their partner interrupts their sleep at least weekly [9].

Core Insights - Tempur-Pedic is collaborating with the National Sleep Foundation (NSF) to investigate why Americans are not sleeping well, combining survey research with real-world sleep data from its Sleeptracker-AI® system [1][2] Company Overview - Tempur Sealy International is a leading designer, manufacturer, distributor, and retailer of bedding products, committed to improving sleep quality globally [6] - The company offers a range of recognized brands, including Tempur-Pedic®, Sealy®, and Stearns & Foster®, and operates in over 100 countries [7] Technology and Innovation - The Sleeptracker-AI technology, developed in partnership with Fullpower-AI®, uses under-mattress sensors to track physiological signals without requiring users to wear devices, providing detailed insights into sleep patterns [4][3] - The platform has been validated through collaboration with Stanford University's Division of Sleep Medicine, ensuring accurate measurement of sleep stages and continuity [4] Research and Development - Upcoming research aims to identify environmental, behavioral, and physiological factors disrupting sleep, which will benefit consumers and the sleep industry [4] - Tempur-Pedic has secured a multi-year extension with Fullpower for exclusive rights to embed Sleeptracker-AI technology in its products until 2036 [3] Industry Engagement - Tempur-Pedic is a gold sponsor of NSF's Sleep Awareness Week® campaign, which promotes the importance of sleep for health and well-being [5]

Financial Data and Key Metrics Changes - The company reported a headline revenue growth of 11% for Q2 FY2026, with a 9% increase on a constant currency basis, resulting in total revenue of $1.42 billion [7][61] - GAAP EPS grew by 16%, reflecting strong double-digit bottom line growth [8] - Gross margin increased by 110 basis points year-over-year to 62.3%, driven by component cost improvements and manufacturing efficiencies [66] - Operating profits rose by 19%, with an operating margin improvement to 36.3% compared to 34% in the prior year [72] Business Line Data and Key Metrics Changes - Global devices revenue experienced high single-digit growth, while masks, accessories, and other revenue saw double-digit growth [9] - Device sales increased by 7% globally on a constant currency basis, while masks and other sales increased by 14% [61] - The Residential Care Software business revenue grew by 5% on a constant currency basis, supported by strong performance from the MEDIFOX DAN software vertical [64] Market Data and Key Metrics Changes - Sales in the U.S., Canada, and Latin America increased by 11%, with a 6% increase on a constant currency basis [62] - In Europe, Asia, and other regions, device sales increased by 5% and masks and other sales increased by 8% on a constant currency basis [64] Company Strategy and Development Direction - The company aims to build a leading digital health ecosystem encompassing sleep health, breathing health, and healthcare technology delivered in the home [15] - ResMed is focused on operational excellence and innovation, with a commitment to maintaining strong free cash flow and a robust balance sheet to support investments and shareholder returns [16][45] - The company is expanding its mask portfolio and enhancing its digital health capabilities, including AI-driven solutions to improve patient adherence to therapy [20][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate global macro uncertainties and highlighted the positive impact of GLP-1 medications on patient engagement and therapy adherence [41][90] - The company is closely monitoring the global trade environment and regulatory landscape, with expectations of continued growth in the sleep health market [42][43] Other Important Information - The company declared a quarterly dividend of $0.60 per share and plans to repurchase shares totaling more than $600 million for FY2026 [76][53] - ResMed's cash balance at the end of Q2 was $1.4 billion, with a solid liquidity position and strong operating cash flows [75] Q&A Session Summary Question: Strong U.S. mask number - Management noted that the strong growth in masks includes contributions from the VirtuOx acquisition, but even without it, there was still double-digit growth in masks and accessories [81][85] Question: Update on GLP-1 landscape - Management confirmed that patients on GLP-1 therapy show a higher motivation to start and adhere to CPAP therapy, with a 10%-11% higher start rate observed [89][92] Question: SG&A growth ahead of revenue growth - Management indicated that the SG&A growth was influenced by the VirtuOx acquisition and marketing programs, but underlying growth was tracking closely with revenue [97] Question: Impact on patient funnel - Management highlighted that the top of the funnel has seen significant progress due to increased awareness from big pharma and tech, and they are focused on scaling home sleep apnea testing [100][102] Question: Philips' potential return to the U.S. market - Management stated uncertainty regarding Philips' re-entry timing and emphasized their focus on current market dynamics and patient flow [128][130]

Financial Data and Key Metrics Changes - ResMed reported an 11% headline revenue growth for Q2 FY2026, with a 9% increase on a constant currency basis, achieving GAAP EPS growth of 16% [7][8][55] - Gross margin increased by 110 basis points year-over-year to 62.3%, driven by component cost improvements and manufacturing efficiencies [58] - Operating profits rose by 19%, with operating margin improving to 36.3% compared to 34% in the prior year [63] Business Line Data and Key Metrics Changes - Global devices revenue grew by high single digits, while masks, accessories, and other revenue saw double-digit growth [9][55] - Residential care software revenue increased by 5% on a constant currency basis, supported by strong performance from the Medifox Dan software vertical [57] Market Data and Key Metrics Changes - In the U.S., Canada, and Latin America, sales increased by 11%, with a 6% increase on a constant currency basis [55] - In Europe, Asia, and other regions, device sales increased by 5% on a constant currency basis, while masks and other sales increased by 8% [56] Company Strategy and Development Direction - ResMed aims to expand its digital health ecosystem, focusing on sleep health and breathing health, while maintaining a strong balance sheet and free cash flow for investments and shareholder returns [14][39] - The company is investing in R&D for next-generation products and enhancing its manufacturing capabilities, including a new distribution center in Indiana [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable high single-digit growth in the residential care software business by FY2027 [11] - The management highlighted the positive impact of GLP-1 medications on patient engagement and adherence to CPAP therapy, indicating a potential tailwind for future growth [78][104] Other Important Information - ResMed returned $263 million to shareholders through dividends and share repurchases during the quarter, with plans to increase share repurchases to over $600 million for FY2026 [67][68] - The company is actively monitoring the global trade environment and regulatory landscape, with no inclusion of CPAP products in CMS's competitive bidding program [37] Q&A Session Summary Question: Strong US mask number - Management noted that the strong growth in masks includes contributions from the Virtuox acquisition, but even without it, there was still double-digit growth in masks and accessories [70][72] Question: Update on GLP-1 landscape - Management confirmed that patients on GLP-1 therapy show a higher motivation to start and adhere to CPAP therapy, with a 10%-11% higher start rate observed [78][80] Question: SG&A growth ahead of revenue growth - Management indicated that the SG&A growth was influenced by the Virtuox acquisition and marketing programs, but underlying growth was tracking closely with revenue [87] Question: Impact of GLP-1 on patient funnel - Management highlighted that GLP-1 medications are bringing more motivated patients into the healthcare system, leading to higher adherence rates for CPAP therapy [80][104] Question: Philips' potential return to the U.S. market - Management stated uncertainty regarding Philips' re-entry into the U.S. market but noted that ResMed is performing well in competing against them in other regions [114][116]

Core Insights - Resmed has received FDA clearance for its Personalized Therapy Comfort Settings (PTCS), branded as Smart Comfort, set to launch in early 2026 for new users of the myAir app paired with the AirSense 11 device [1][9] - Smart Comfort is designed to enhance the user experience in CPAP therapy by utilizing AI and real-world sleep data to provide personalized comfort settings [2][5] Company Developments - Resmed's Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings for patients with obstructive sleep apnea (OSA), which affects an estimated 61 million people in the U.S. [3][9] - The company currently has a market capitalization of $37.44 billion, with a projected 13.2% increase in fiscal 2026 earnings according to the Zacks Consensus Estimate [4] Product Features - Smart Comfort addresses common therapy issues such as comfort and mask fit, promoting long-term adherence to CPAP therapy by leveraging machine-learning algorithms and over 100 million nights of de-identified sleep data [5][6] - The device settings include features that ease users into therapy, adjust pressure gradually, and reduce pressure on exhalation, developed with clinical oversight and ethical data use [6][7] Market Outlook - The global sleep apnea device market is valued at $7.11 billion in 2025, with a projected compound annual growth rate of 7% through 2034, driven by the rising prevalence of sleep apnea and advancements in medical technology [11] - Resmed's recent initiatives, such as the launch of the Sleep Institute, aim to advance the science of sleep health and support policy decisions [12] Stock Performance - Following the announcement of Smart Comfort, Resmed's shares dropped 2.5%, closing at $250.04, but the product is expected to support a rebound in stock performance [3] - Year-to-date, Resmed shares have increased by 9.3%, outperforming the industry average of 3.2% [13]

What if every bad decision you’ve made started with your sleep? Many of us see sleep as rest, but in reality it’s the foundation for everything we do in life. Today I’m joined for the second time by Matthew Walker, a neuroscientist who has spent years studying the impact of sleep on the brain and the body. He sees sleep as the social ‘glue’ that keeps us together. This time, Matthew brought me through his ‘QQRT’ framework - a simple way for all of us to measure our sleep health. We cover: - Why does the las ...

Core Insights - Resmed has launched the Sleep Institute, a global clinical insights initiative aimed at advancing the science and understanding of sleep health [1][2][3] Group 1: Initiative Overview - The Sleep Institute partners with clinicians, researchers, policymakers, and health system leaders to provide evidence-based insights that inform care innovation and elevate sleep as a global health priority [2][3] - The initiative aims to address the significant underdiagnosis of sleep disorders, particularly obstructive sleep apnea (OSA), which affects an estimated 1 billion people globally [3][5] Group 2: Research and Findings - A U.S. consumer survey revealed that while over 80% of respondents consider sleep important for their health, only one-third have been asked about their sleep by a healthcare professional in the past six months, highlighting a gap in routine healthcare discussions [4][6] - The Sleep Institute will publish original research and real-world data to support earlier and more accurate diagnoses of sleep disorders [3][4] Group 3: Symposium and Collaboration - The Sleep Institute will debut at the World Sleep Congress with a symposium focused on the underdiagnosis of OSA, featuring clinical leaders from various countries [5][6] - The symposium aims to identify barriers in diagnostic pathways and propose scalable solutions to improve access and outcomes in sleep health [5][6] Group 4: Goals and Vision - The overarching goal of the Sleep Institute is to act as a catalyst for earlier diagnosis, stronger policies, and improved outcomes in sleep health worldwide [6][8] - Resmed envisions a future where better sleep and breathing can help individuals achieve their full potential, with care delivered in their homes [9]

Core Insights - Resmed has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia, highlighting its commitment to promoting sleep health in sports [1][3][6] Company Overview - Resmed is a leading health technology company focused on sleep, breathing, and home care, aiming to empower individuals to live healthier lives through innovative technologies [1][13] - The company operates in 140 countries and emphasizes the importance of quality sleep as a critical component of overall health [13] Campaign Details - The 'Tackle Your Sleep' campaign will feature legendary rugby players and aims to raise awareness about sleep health issues affecting both players and fans [3][5] - The campaign will provide advice and tools to improve sleep quality, emphasizing its significance alongside exercise and diet [3][5] Health Implications - Poor sleep can negatively impact mental and physical health, relationships, and daily performance, particularly for athletes [4][5] - A study indicated that half of the rugby and cricket players surveyed were classified as poor sleepers, with many experiencing significant daytime fatigue [4][5] Tour Information - The British & Irish Lions Tour will take place over six weeks, featuring matches in six cities across Australia, with an estimated 40,000 fans participating [2][8] - The Lions will play a total of 10 matches, including three Test matches against the Wallabies [8]